Last updated: February 15, 2026
Overview
NDC 51672-4023 corresponds to Doxycycline Hyclate delayed-release capsules, primarily used for treating bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections. The drug's patent status, manufacturing landscape, and market demand influence its pricing and market trajectory.
Market Size and Demand
-
The global antibiotics market was valued at approximately $56 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.2% through 2030 (MarketWatch).
-
Doxycycline's market segments include general antibiotics, special formulations, and branded versus generic products.
-
In the United States, outpatient prescribing of doxycycline totaled about 12 million prescriptions annually as of 2022, reflecting steady demand driven by infectious disease prevalence and resistance patterns.
-
Resistance trends and inventory levels affect regional and global demand, with increased use in developing countries due to affordability.
Market Share and Competitive Landscape
-
Doxycycline Hyclate faces competition from other tetracyclines and newer antibiotics like minocycline and doxycycline generics.
-
Leading manufacturers include Teva Pharmaceuticals, Mylan (now part of Viatris), and Sandoz, each holding substantial market shares.
-
The market for doxycycline is characterized by high generic penetration, which exerts downward pressure on prices.
Pricing Analysis
-
Retail pharmacy prices for doxycycline Hyclate 100 mg capsules vary geographically but typically range from $0.25 to $0.50 per capsule when purchased generically.
-
Wholesale acquisition costs (WAC) for brand-name formulations tend to be around $1.00 per capsule, with discounts negotiated by pharmacies.
-
The typical prescription involves a course of 14 to 21 days, with total pharmacy costs averaging between $14 and $30 per treatment course.
-
For the delayed-release formulation (NDC 51672-4023), pricing tends to be at the higher end of the spectrum due to manufacturing complexity, with average retail costs approximately 10-15% higher than immediate-release formulations.
Price Projections (2023–2028)
| Year |
Price Range per Capsule |
Notes |
| 2023 |
$0.30 - $0.55 |
Stable due to high generic availability; minor variations depend on supplier. |
| 2024 |
$0.28 - $0.52 |
Slight discount trend due to increased generic competition. |
| 2025 |
$0.27 - $0.50 |
Further reductions expected as new generics enter the market. |
| 2026 |
$0.25 - $0.48 |
Market stabilization; price competition persists. |
| 2027 |
$0.25 - $0.46 |
Price plateau with occasional minor fluctuations. |
| 2028 |
$0.24 - $0.45 |
Expected near-bottom price due to saturation of generics. |
Key Drivers for Price Trends
-
Market saturation with generic doxycycline reduces prices over time.
-
Supply chain stability influences manufacturing costs; shortages could temporarily increase prices.
-
Regulatory policies and patent expirations facilitate new entrants, intensifying price competition.
-
Clinical guidelines favoring doxycycline for specific infections bolster consistent demand, supporting stable margins despite price reductions.
Regulatory and Patent Landscape
-
Doxycycline Hyclate's patent expired in the U.S. in the late 1990s.
-
The delayed-release formulation (NDC 51672-4023) is likely a modified-release patent-protected version; patent expirations or challenges could further drive price decreases.
-
FDA approval status remains unaltered, with no current indications for exclusivity extension.
Market Risks and Opportunities
-
Rising antibiotic resistance may increase demand for doxycycline in resistant infection cases, potentially maintaining prices.
-
Competition from new antibiotics and alternative formulations might suppress pricing.
-
Development of combination therapies or novel delayed-release formulations could create niche markets or demand for premium pricing.
Summary
Doxycycline Hyclate delayed-release capsules (NDC 51672-4023) are heavily commoditized with a high supply of generics resulting in declining prices. Price projections indicate stabilization at lower levels over the next five years, with slight downward trends driven by market saturation and generic competition. Demand remains steady due to broad clinical indications, but pricing sustainability hinges on resistance patterns and regulatory environment.
Key Takeaways
-
Market for NDC 51672-4023 is mature, dominated by generics, with price declines ongoing since patent expiry.
-
Current retail prices for capsules range from $0.25 to $0.55, with expected gradual reductions.
-
Demand remains stable, driven by widespread antibiotic use and resistance considerations.
-
Competition and patent expirations are primary factors influencing future price decreases.
-
Opportunities for premium pricing relate to formulation innovations and resistance-driven demand.
FAQs
1. What factors most influence the price of doxycycline delayed-release capsules?
Market saturation with generics, competition from new entrants, manufacturing costs, and resistance-driven demand shape pricing. Patent status and regulatory changes also impact prices.
2. How does the delayed-release formulation affect pricing compared to immediate-release doxycycline?
The delayed-release version typically commands higher prices—approximately 10-15% above immediate-release due to manufacturing complexity and patent protections. Over time, as patents expire, prices tend to converge with generic immediate-release formulations.
3. Is there potential for price increases in the near future?
Short-term price increases are unlikely unless supply shortages occur or resistance patterns significantly boost demand. Competition and patent challenges tend to favor price reductions over time.
4. What are the major competitors for this product?
Generic doxycycline Hyclate from multiple manufacturers, alternative tetracyclines like minocycline, and newer antibiotics offer competition. No significant branded threats currently exist due to patent expiration.
5. How might regulatory policies impact the market?
Patents or exclusivity periods influencing delayed-release formulations can sustain higher prices temporarily. Changes in FDA policies or approval pathways may accelerate generic entry, further lowering prices.
References
- MarketWatch. "Global Antibiotics Market Size & Share." 2022 report.
- IQVIA. "Outpatient Antibiotic Sales Data," 2022.
- FDA. "Drug Approvals and Patent Data," 2022.
- SSR Health. "Generic Drug Price Trends," 2023.
